ASX Announcements
Memphasys is committed to providing shareholders with complete, up-to-the-minute information about the Company. Contact, stock, and corporate information can be found in this section of the website and on the Australian Securities Exchange.
30 November Executive transition and Capital Raise
31 October 2023 Quarterly Activity Report and Appendix 4C
26 September 2023 Investor Presentation – September 2023, Human & Animal Programs
15 September 2023 FelixTM System successfully records 10 new live births in India
14 August 2023 Initial FelixTM System order placed by Vitrolife Japan
7 August 2023 Memphasys signs exclusive Japanese Felix TM distribution agreement with Vitrolife
28 July 2023 Quarterly Activities/Appendix 4C Cash Flow Report
13 July 2023 New Patents granted for Felix System
6 June 2023 Felix considered best method to treat cryopreserved semen
28 April 2023 Quarterly Activities/Appendix 4C Cash Flow Report
5 April 2023 Investor presentation April 2023
3 April 2023 Japan first commercial sale and first baby born using Felix
30 March 2023 Experienced fertility expert appointed Operations Director
28 February 2023 Highly-credentialled exec appointed as Director of BusDev
24 February 2023 Half Yearly Report and Accounts
7 February 2023 KOL testings demonstrate Felix System outperforms DGC
31 January 2023 December Quarterly Activities/Appendix 4C Cash Flow Report
27 October 2022 September Quarterly Activities/Appendix 4C Cash Flow Report
25 October 2022 Notice of Annual General Meeting/Proxy Form
24 October 2022 FELIX System commercialisation, regulatory plan and trial
21 September 2022 Appendix 2A- Application for Quotation of Securities
19 September 2022 Rights Issue Closure and Shortfall Notification
5 September 2022 Non-Renounceable Issue
5 September 2022 Appendix 3B
31 August 2022 Full Year Statutory Accounts
31 August 2022 Preliminary Final Report
31 August 2022 Appendix 4G and Corporate Governance Statement
29 August 2022 Rights Issue Prospectus despatched
25 August 2022 Application for quotation of securities
18 August 2022 Rights Issue offer – Letter to ineligible shareholders
18 August 2022 Non-Renounceable Issue – Website Disclaimer
18 August 2022 Update – Proposed issue of securities – MEM
17 August 2022 Proposed issue of securities – MEM
17 August 2022 Reinstatement to Official Quotation
17 August 2022 $3.36 capital raising to accelerate FELIX commercialisation
11 August 2022 Court Orders Granted and update on Proposed Capital Raising
2 August 2022 Cleansing Statement
29 July 2022 Quarterly Activities/Appendix 4C Cash Flow Report
29 July 2022 Suspension from Official Quotation
27 July 2022 Trading Halt
28 June 2022 Monash IVF clinical study enrols first patient using FELIX
27 June 2022 Notification of cessation of securities – MEM
9 June 2022 Felix System commercialisation update
6 June 2022 Notification of cessation of securities – MEM
17 May 2022 Response to ASX Query
26 April 2022 Final Director’s Interest Notice SH
26 April 2022 Initial Director’s Interest Notice – RC
26 April 2022 Non-Exec Chair Appointment and Director Resignation
12 April 2022 Quarterly Activities/Appendix 4C Cash Flow Report
3 Mar 2022 Creating Novel fertility Solutions
25 Jan 2022 Quarterly Activities/Appendix 4C Cash Flow Report
24 Jan 2022 Change of Directors Interest Notice
19 Jan 2022 Sale of existing Convertible Note to Peters Investments Pty Ltd
20 Dec 2021 Memphasys secures first Felix™ System commercial sale for clinical IVF use
9 Oct 2021 Change of director’s interest notice
28 Sep 2021 Cleansing Notice – Section 708A(5)(e)
28 Sep 2021 Application for quotation of securities – MEM
20 Sep 2021 Acceleration of reproductive biotechnology portfolio
17 Sep 2021 Appendix 3G correction
17 Sep 2021 Notification regarding unquoted securities
10 Sep 2021 Change of Director’s Interest Notice – AC and AG
3 Sep 2021 Appendix 3G
1 Sep 2021 Notification regarding unquoted securities – MEM
1 Sep 2021 MEM reaches settlement agreement with Hydrix
31 Aug 2021 Commercial arrangement between Hydrix and Memphasys
31 Aug 2021 FY21 Corporate Governance Statement and Appendix 4G
30 Aug 2021 FY21 Full Year Statutory Accounts
30 Aug 2021 Preliminary Final Report
24 Aug 2021 Results of General Meeting
20 Aug 2021 General Meeting to be held as a Virtual Meeting of members
30 Jul 2021 Disclosure Document – Cleansing Notice
30 Jul 2021 Application for quotation of securities – MEM
30 Jul 2021 Notification regarding unquoted securities – MEM
26 Jul 2021 Quarterly Activities/Appendix 4C Cash Flow Report
23 Jul 2021 Notice of General Meeting/Proxy Form
5 Jul 2021 Global andrology expert, Professor John Aitken, joins MEM
1 Jul 2021 Upgraded Felix Device verification passed
26 May 2021 Proposed issue of Securities – MEM
26 May 2021 Memphasys completes $3m capital raise
25 May 2021 Trading Halt
4 May 2021 Assisted reproductive biotechnology products update
4 May 2021 Prof. John Aitken receives distinguished andrology award
30 Apr 2021 Quarterly Cashflow Report
29 Apr 2021 Granted US patents strengthens IP portfolio
27 Apr 2021 Felix device – V&V progress and KOL study update
30 Mar 2021 FELIX device Verification and Validation process update
8 Mar 2021 Felix device validation testing delayed
26 Feb 2021 Half Yearly Report and Accounts
17 Feb 2021 Change of Director’s Interest Notice – Coutts
17 Feb 2021 Cancellation of Performance Options
2 Feb 2021 Disclosure Document – s708A cleansing notice
2 Feb 2021 Appendix 2A option conversion